There is currently an unmet need for targeted lung cancer therapy with improved central nervous system penetration and activity against central nervous system metastases. This study on “CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)” is the first global phase III study to show osimertinib having robust and durable efficacy against central nervous system metastases and disease progression (J Clin Oncol. 2018 Jul 30:JCO2018779363. doi: 10.1200/JCO.2018.77.9363. [Epub ahead of print]).